Ongoing Task Forces

Task Force on Immunopharmacology: small molecule-based therapies in allergy and clinical immunology

Rationale:
Current development of new safe and effective therapies for respiratory diseases is taking longer, costs more and is less successful (see Barnes Nature Rev Drug Discovery 2013;12:543).
In the last decade, high-throughput research technology and systems biology are logarithmically expanding our understanding of molecular networks underlying airway disease pathogenesis, leading to discovery or better definition of targetable pathways and disease phenotypes. This new knowledge is especially important for the unmet need of new therapies for disease phenotypes not controlled by current regimens.
Along with the success of biologics for treating allergic- and immune-mediated conditions such as severe asthma, LES, rheumatoid arthritis, small molecule-based therapies remain an active field in drug R&D.
Small molecule agents expand biologics’ therapeutic targets by reaching the intracellular compartment and can be developed into oral- or topical-based medications, which offers convenience and cost reduction.

Aims:
The TF’ s objective is to gather a multidisciplinary group - physicians, basic scientists, pharmacologists, computational biologists - examining recent breakthroughs on mechanisms of immune regulation and therapeutic approaches exploitable in Allergy and Clinical Immunology in order to:

• review recent basic, preclinical and clinical research in the area of small molecule inhibitors for the treatment of allergic and autoimmune diseases and describe the pathways most amenable – and most pursued – for this approach;
• Compare small molecules versus antibody-driven approaches: molecular mechanisms, clinical aspects, pharmaeconomics;
• Compare the main opportunities and challenges associated to these therapeutic strategies, as well as the relationship with conventional therapies and combination approaches;
• Point to recent breakthroughs on basic mechanisms of immune regulation that could be targetable by small molecule inhibitors for the treatment of allergic and autoimmune diseases.

Outcomes and possible benefits for EAACI:
It is expected that the multidisciplinary TF group will:

• Generate a collective manuscript highlighting the current state of knowledge and the TF critical conclusions, which will be a valuable resource for the EAACI community and the allergy/clinical immunology community at large;
• Communicate scientific advances and achievements to the EAACI community in dedicated and/or general EAACI meetings;
• Generate proposals for Interest Groups at the Immunology Section and for dedicated sessions for upcoming scientific programmes of EAACI meetings;
• Potentially develop an EAACI summer school program, directed to multidisciplinary scholars (medicine and biology, pharmacology, bioengineering, computational mathematics) involved in basic, translational and pharmaceutical research in allergy and clinical immunology.

Overall, the Task Force in Immunopharmacology will further EAACI’s role as a leading society in sustainable treatment of immune and allergic disorders.

Cristiana Stellato Chairperson: Cristiana Stellato, MD, PhD
Associate Professor, Department of Medicine, Surgery and Dentistry
"Scuola Medica Salernitana", University of Salerno , Salerno, Italy
This email address is being protected from spambots. You need JavaScript enabled to view it.
Franziska Roth Walter Secretary: Franziska Roth-Walter, PhD
Assistant Professor
Comparative Medicine, The Interuniversity Messerli Research Institute of
the University of Veterinary Medicine Vienna, Medical University Vienna
and University Vienna, Vienna, Austria
This email address is being protected from spambots. You need JavaScript enabled to view it.

Members
 Adcock Ian Adcock, PhD
Professor of Respiratory Cell & Molecular Biology; Head, Molecular Cell
Biology Group, National Heart & Lung Institute, Imperial College London,
United Kingdom
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Bianchini Rodolfo Bianchini, PhD
Senior Scientist, Comparative Medicine, The Interuniversity Messerli
Research Institute of the University of Veterinary Medicine Vienna, Medical
University Vienna and University Vienna, Vienna, Austria
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Bjermer Leif Bjermer, MD
Professor, Head, Department of Respiratory Medicine and Allergology,
Lung and allergy research, Allergy, Asthma and COPD Competence
center, Lund University, Lund, Sweden
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Caramori Gaetano Caramori, MD, PhD
Full Professor of Respiratory Diseases, Unità Operativa Complessa di
Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle
Immagini Morfologiche e Funzionali (BIOMORF), Università degli Studi di
Messina, Italy
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Cari Luigi Cari, PhD student
PhD student, Department of Medicine, Section of Pharmacology,
University of Perugia, Perugia Italy
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Chung Kian Fan Chung, MD, DSc
Professor of Respiratory Medicine; Head, Experimental Studies Medicine
at National Heart & Lung Institute, Imperial College London; Consultant
Physician, Royal Brompton & Harefield NHS Trust, London, UK
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Zuzana Diamant Zuzana Diamant, MD, PhD
Executive Medical Director/Director Respiratory & Allergy, QPS-NL,
Department of Clinical Pharmacy & Pharmacology and
Department of General Practice, UMCG, Groningen, The Netherlands
Professor of Respiratory Medicine & Allergology,
Department of Respiratory Medicine & Allergology,
Institute for Clinical Science, Skane University Hospital, Lund, Sweden

 Eguiluz Gracia Ibon Eguíluz-Gracia, MD PhD
Allergy consultant and Post-doctoral researcher
Allergy Unit and Research Laboratory, Regional University Hospital of
Málaga and Biomedical Research Institute of Malaga (IBIMA). Málaga,
Spain
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Knol Edward Knol, PhD
Associate Professor, Departments of Immunology and
Dermatology/Allergology, University Medical Center Utrecht,
The Netherlands
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Kolios Antonios, Kolios, MD
Dermatologist and Venerologist, Consultant, University Hospital Zurich,
Department of Immunology, Zurich, Switzerland
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Levi Schaffer Francesca Levi – Schaffer, PharmD, PhD
Professor, Institute for Drug Research, School of Pharmacy, Faculty of
Medicine, The Hebrew University of Jerusalem, Israel
This email address is being protected from spambots. You need JavaScript enabled to view it.
 Nocentini Giuseppe Nocentini, MD, PhD
Associate Professor, Chair of Pharmacology, Department of Medicine,
Section of Pharmacology, University of Perugia, Perugia Italy
 Palomares Oscar Palomares, PhD
Ramón y Cajal Associate Researcher, Department of Biochemistry and
Molecular Biology,
School of Chemistry, Complutense University of Madrid, Madrid, Spain
This email address is being protected from spambots. You need JavaScript enabled to view it.
Pier Giorgio Puzzovio  Pier Giorgio Puzzovio
PhD student, Institute for Drug Research, School of Pharmacy,
Faculty of Medicine, The Hebrew University of Jerusalem, Israel
This email address is being protected from spambots. You need JavaScript enabled to view it.

 Redegeld Frank Redegeld, PhD  
Associate Professor, Faculty of Science, Division of Pharmacology,
Department of Pharmaceutical Sciences, Utrecht University,
The Netherlands
This email address is being protected from spambots. You need JavaScript enabled to view it.
Betty Van Esch Betty Van Esch, PhD
Senior Scientist; Division of Pharmacology, Department of Pharmaceutical Sciences, UIPS, Utrecht University, the Netherlands
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cristina Benito Villavilla Cristina Benito Villavilla, PhD student
Ramón y Cajal Associate Researcher, Department of Biochemistry and Molecular Biology,
School of Chemistry, Complutense University of Madrid, Madrid, Spain
This email address is being protected from spambots. You need JavaScript enabled to view it.

Last updated 13 December 2017